Trial Profile
Open-label, Single Arm, Two-stage Study, Evaluating the Efficacy and Safety of Bimiralisib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (HNSCC) Harboring NOTCH1 Loss of Function (LOF) Mutations
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Bimiralisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HNSCC
- Sponsors PIQUR Therapeutics
- 09 Dec 2022 Results assessing the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant head and neck squamous cell carcinoma, published in the Oncologist.
- 09 Nov 2021 Status changed from completed to discontinued.
- 23 Feb 2021 Status changed from recruiting to completed.